Abstract：
OBJECTIVE: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccines have been reported to trigger immune side effects. Type 1 diabetes as a manifestation of autoimmune/inflammatory syndrome induced by adjuvants has been reported in a limited number of cases after vaccinations. A few type 1 diabetes cases after SARS-CoV-2 vaccination have been reported. This study aims to report type 1 diabetes cases associated with the mRNA-based SARS-CoV-2 vaccination.
METHODS: We report four cases of type 1 diabetes mellitus after mRNA-based SARS-CoV-2 vaccine, BNT162b2 (Pfizer-BioNTech). In the medical history, one subject had autoimmune thyroid disease. All patients had autoantibodies against glutamate decarboxylase.
RESULTS: In the presented case series, type 1 diabetes developed a few weeks after BNT162b2 vaccination. After developing type 1 diabetes, the insulin dose requirements of all patients decreased rapidly, and the need for insulin therapy in three patients disappeared during follow-up. Acute deterioration of glucose regulation in a patient followed by BNT162b2 administration may be due to vaccine-induced autoimmune diabetes.
CONCLUSIONS: Vaccination with BNT162b2 may trigger type 1 diabetes.
METHODS: We report four cases of type 1 diabetes mellitus after mRNA-based SARS-CoV-2 vaccine, BNT162b2 (Pfizer-BioNTech). In the medical history, one subject had autoimmune thyroid disease. All patients had autoantibodies against glutamate decarboxylase.
RESULTS: In the presented case series, type 1 diabetes developed a few weeks after BNT162b2 vaccination. After developing type 1 diabetes, the insulin dose requirements of all patients decreased rapidly, and the need for insulin therapy in three patients disappeared during follow-up. Acute deterioration of glucose regulation in a patient followed by BNT162b2 administration may be due to vaccine-induced autoimmune diabetes.
CONCLUSIONS: Vaccination with BNT162b2 may trigger type 1 diabetes.
摘要：
目的：据报道，严重急性呼吸系统综合症冠状病毒2（SARS-CoV-2）疫苗会引发免疫副作用。1型糖尿病作为由佐剂诱导的自身免疫/炎症综合征的表现已经在接种疫苗后的有限数量的病例中报道。已经报道了一些SARS-CoV-2疫苗接种后的1型糖尿病病例。这项研究旨在报告与基于mRNA的SARS-CoV-2疫苗接种相关的1型糖尿病病例。
方法：我们报告了4例基于mRNA的SARS-CoV-2疫苗后的1型糖尿病，BNT162b2（辉瑞生物技术公司）。在病史中,一名受试者患有自身免疫性甲状腺疾病.所有患者都有抗谷氨酸脱羧酶的自身抗体。
结果：在本案例系列中，1型糖尿病在接种BNT162b2疫苗后几周出现。发展为1型糖尿病后，所有患者的胰岛素剂量需求迅速下降，在随访期间，3例患者对胰岛素治疗的需求消失了。在BNT162b2给药之后的患者中葡萄糖调节的急性恶化可能是由于疫苗诱导的自身免疫性糖尿病。
结论：接种BNT162b2疫苗可能引发1型糖尿病。
方法：我们报告了4例基于mRNA的SARS-CoV-2疫苗后的1型糖尿病，BNT162b2（辉瑞生物技术公司）。在病史中,一名受试者患有自身免疫性甲状腺疾病.所有患者都有抗谷氨酸脱羧酶的自身抗体。
结果：在本案例系列中，1型糖尿病在接种BNT162b2疫苗后几周出现。发展为1型糖尿病后，所有患者的胰岛素剂量需求迅速下降，在随访期间，3例患者对胰岛素治疗的需求消失了。在BNT162b2给药之后的患者中葡萄糖调节的急性恶化可能是由于疫苗诱导的自身免疫性糖尿病。
结论：接种BNT162b2疫苗可能引发1型糖尿病。
